The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

Hot Stocks}BYD ELECTRONIC(00285) quoted at HK$41.6, up 2.8% 09/01/2025 10:02 {Hot Stocks}TECHTRONIC IND(00669) quoted at HK$99.9, up 3.2% 09/01/2025 09:57 {Hot Stocks}LENOVO GROUP(00992) quoted at ...

Hot Stocks}HANSOH PHARMA(03692) quoted at HK$16.74, up 3.2% 09/01/2025 09:51 {Hot Stocks}SMIC(00981) quoted at HK$32.2, up 5.4% 09/01/2025 09:48 {Hot Stocks}ZHONGSHENG HLDG quoted at HK$12.34, down 3.

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

UK pharma major GSK today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate ...

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.